Nagihan Ayaz Naycı
Research Subjects
Nagihan Ayaz Naycı has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aybeniz Civan Kahve
Department of Psychiatry, Faculty of Medicine, Gazi University, Türkiye
3 shared publications - Erol Göka
Department of Psychiatry, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
3 shared publications - Andaç Uzdoğan
Department of Biochemistry, Ankara Bilkent City Hospital, Ankara, Turkey
2 shared publications - Hasan Kaya
University of Health Sciences, Ankara Bilkent City Hospital
2 shared publications - Yağmur Darben Azarsız
Department of Psychiatry, Barış Mental and Neurological Diseases Hospital, Nicosia, Northern Cyprus
2 shared publications - Abdulkadir Kaya
Giresun Üniversitesi
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (6) , 1269-1278
Effects of lithium use on renal structure in smoking patients with bipolar disorder: a computed tomography-based volumetric study
Aims: To evaluate the association between lithium and renal structure using computed tomography (CT)-based volumetric methods in smoking patients with bipolar disorder, and its relationship with renal function indicators.Methods: This retrospective, cross-sectional, single-center study included 165 participants with contrast-enhanced abdominal CT: smoking patients with bipolar disorder receiving lithium (n=55), lithium-naïve smoking patients with bipolar disorder (n=55), and smoking controls without known psychiatric or renal disease (n=55). Renal parenchymal volume, dimensions, cortical thickness at four sites, and cystic changes were assessed by two radiologists using 3D Slicer software; volumes were normalized to body surface area (BSA). Serum creatinine, estimated glomerular filtration rate (eGFR), and other biochemical parameters were recorded.Results: Interobserver agreement was high (ICC=0.81). In unadjusted analysis, eGFR differed among groups (p=0.037) and was lower in the lithium group than in controls (difference between group medians, 8.8 ml/min/1.73 m²; p=0.011), but this difference was no longer significant after adjustment for age, gender, body-mass index (BMI), and pack-years (p=0.503); creatinine did not differ (p=0.586). In unadjusted comparisons, renal parenchymal volume, dimensions, and BSA-normalized volume did not differ among groups (all p>0.09). Right lower-pole cortical thickness showed an isolated unadjusted difference between the lithium and non-lithium groups (p=0.016) that did not survive correction for the four regional comparisons. Renal cyst frequency was similar among groups (p=0.572). Total renal volume correlated positively with height, weight, and BMI. In these adjusted models, BSA-normalized renal volume was significantly lower in the lithium group than in controls (B=-22.8 cm³/m², 95% CI -41.0 to -4.7; p=0.014), a difference not apparent in the unadjusted comparison.Conclusion: Although unadjusted eGFR was lower in lithium-treated patients with bipolar disorder than in controls, this difference did not persist after covariate adjustment for age, gender, BMI, and smoking exposure. Renal parenchymal volume, dimensions, and cyst frequency did not differ significantly on unadjusted comparison, although BSA-normalized renal volume was significantly lower in the lithium group after covariate adjustment. These findings suggest that the unadjusted eGFR difference is not robust to adjustment for baseline demographic and clinical characteristics, while a confounder-adjusted difference in normalized renal volume between the lithium group and controls represents a novel finding that warrants confirmation in prospective studies.
- 25 October 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (6) , 1269-1278
Open AccessEffects of lithium use on renal structure in smoking patients with bipolar disorder: a computed tomography-based volumetric study
Aims: To evaluate the association between lithium and renal structure using computed tomography (CT)-based volumetric methods in smoking patients with bipolar disorder, and its relationship with renal function indicators.Methods: This retrospective, cross-sectional, single-center study included 165 participants with contrast-enhanced abdominal CT: smoking patients with bipolar disorder receiving lithium (n=55), lithium-naïve smoking patients with bipolar disorder (n=55), and smoking controls without known psychiatric or renal disease (n=55). Renal parenchymal volume, dimensions, cortical thickness at four sites, and cystic changes were assessed by two radiologists using 3D Slicer software; volumes were normalized to body surface area (BSA). Serum creatinine, estimated glomerular filtration rate (eGFR), and other biochemical parameters were recorded.Results: Interobserver agreement was high (ICC=0.81). In unadjusted analysis, eGFR differed among groups (p=0.037) and was lower in the lithium group than in controls (difference between group medians, 8.8 ml/min/1.73 m²; p=0.011), but this difference was no longer significant after adjustment for age, gender, body-mass index (BMI), and pack-years (p=0.503); creatinine did not differ (p=0.586). In unadjusted comparisons, renal parenchymal volume, dimensions, and BSA-normalized volume did not differ among groups (all p>0.09). Right lower-pole cortical thickness showed an isolated unadjusted difference between the lithium and non-lithium groups (p=0.016) that did not survive correction for the four regional comparisons. Renal cyst frequency was similar among groups (p=0.572). Total renal volume correlated positively with height, weight, and BMI. In these adjusted models, BSA-normalized renal volume was significantly lower in the lithium group than in controls (B=-22.8 cm³/m², 95% CI -41.0 to -4.7; p=0.014), a difference not apparent in the unadjusted comparison.Conclusion: Although unadjusted eGFR was lower in lithium-treated patients with bipolar disorder than in controls, this difference did not persist after covariate adjustment for age, gender, BMI, and smoking exposure. Renal parenchymal volume, dimensions, and cyst frequency did not differ significantly on unadjusted comparison, although BSA-normalized renal volume was significantly lower in the lithium group after covariate adjustment. These findings suggest that the unadjusted eGFR difference is not robust to adjustment for baseline demographic and clinical characteristics, while a confounder-adjusted difference in normalized renal volume between the lithium group and controls represents a novel finding that warrants confirmation in prospective studies.
- 20 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 397, 120979
Serum FGF21 and GDF15 levels and their association with cognitive function in bipolar disorder
- 20 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 397, 120979
Serum FGF21 and GDF15 levels and their association with cognitive function in bipolar disorder
- 8 November 2024
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 96 (1) , 19-37
Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?
This study aimed to evaluate the role of neuroinflammation in neuronal and glial cells in the pathophysiology of Major Depressive Disorder (MDD) through different biomarkers.S100-B and VILIP-1 levels of patients diagnosed with MDD were evaluated before and after antidepressant treatment. A total of 65 patients diagnosed with MDD and 69 healthy controls were included. Serum levels of S100B and VILIP-1 were measured at the time of diagnosis and after eight weeks antidepressant treatment and compared with healthy controls. Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression Scale (CGI) were applied to assess the severity of depression. In our study, although serum S100B levels were higher in patients before treatment compared to healthy controls, this difference was not statistically significant. Regarding VILIP-1 levels, there was no statistically significant difference between patients and healthy controls. A positive and statistically significant correlation was found between S100B and VILIP-1 levels in MDD group before the treatment. At the eighth week of treatment, a statistically significant positive correlation was also found between S100B and VILIP-1 levels. Our research is the first study to evaluate MDD through two separate biomarkers specific to glial and neuronal cells.The fact that S100B and VILIP-1 levels showed significant correlations in patients diagnosed with MDD both before and after treatment suggests that they may play a shared role in the pathophysiology of the disorder. The correlation between S100B and VILIP-1 may serve as a guide in understanding the pathophysiology of the disorder and in identifying new drug development targets.
- 8 November 2024
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 96 (1) , 19-37
Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?
This study aimed to evaluate the role of neuroinflammation in neuronal and glial cells in the pathophysiology of Major Depressive Disorder (MDD) through different biomarkers.S100-B and VILIP-1 levels of patients diagnosed with MDD were evaluated before and after antidepressant treatment. A total of 65 patients diagnosed with MDD and 69 healthy controls were included. Serum levels of S100B and VILIP-1 were measured at the time of diagnosis and after eight weeks antidepressant treatment and compared with healthy controls. Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression Scale (CGI) were applied to assess the severity of depression. In our study, although serum S100B levels were higher in patients before treatment compared to healthy controls, this difference was not statistically significant. Regarding VILIP-1 levels, there was no statistically significant difference between patients and healthy controls. A positive and statistically significant correlation was found between S100B and VILIP-1 levels in MDD group before the treatment. At the eighth week of treatment, a statistically significant positive correlation was also found between S100B and VILIP-1 levels. Our research is the first study to evaluate MDD through two separate biomarkers specific to glial and neuronal cells.The fact that S100B and VILIP-1 levels showed significant correlations in patients diagnosed with MDD both before and after treatment suggests that they may play a shared role in the pathophysiology of the disorder. The correlation between S100B and VILIP-1 may serve as a guide in understanding the pathophysiology of the disorder and in identifying new drug development targets.
- Open Access
- 1 January 2024
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 46, 1-21
Evaluation of galectin-1 and galectin-3 levels in patients with bipolar disorder: is galectin-3 associated with treatment response?
Galectins (Gal) were linked with inflammatory responses in the central nervous system, may play an important role in the pathogenesis of BD.In this study,we aimed to investigate whether serum Gal-1 and Gal-3 levels are related to BD. 36 patients diagnosed with BD were included.C-Reactive Protein(CRP),Gal-1,Gal-3 blood levels were evaluated on the first day of hospitalization and the third week of treatment and compared with 41 healthy controls.The severity of the illness was evaluated with the Young Mania Rating Scale (YMRS). CRP levels of BD patients at hospitalization were significantly higher than the third week of treatment and healthy controls.Gal-1 levels on the first day of hospitalization and the third week of treatment were found higher than the healthy controls.There was no significant difference in Gal-3 levels of the patients on the day of hospitalization compared to healthy controls;at the end of the 3rd week of treatment,Gal-3 was statistically significantly higher than the first day of hospitalization. Our study is valuable in that it is the first study to show the change in Gal levels after treatment and to evaluate the role of Gal in BD.Gal-1 may play roles in the pathophysiology of BD.Gal-3 may be a biomarker candidate for the evaluation of the treatment response.
- 1 January 2024
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 46, 1-21
Open AccessEvaluation of galectin-1 and galectin-3 levels in patients with bipolar disorder: is galectin-3 associated with treatment response?
Galectins (Gal) were linked with inflammatory responses in the central nervous system, may play an important role in the pathogenesis of BD.In this study,we aimed to investigate whether serum Gal-1 and Gal-3 levels are related to BD. 36 patients diagnosed with BD were included.C-Reactive Protein(CRP),Gal-1,Gal-3 blood levels were evaluated on the first day of hospitalization and the third week of treatment and compared with 41 healthy controls.The severity of the illness was evaluated with the Young Mania Rating Scale (YMRS). CRP levels of BD patients at hospitalization were significantly higher than the third week of treatment and healthy controls.Gal-1 levels on the first day of hospitalization and the third week of treatment were found higher than the healthy controls.There was no significant difference in Gal-3 levels of the patients on the day of hospitalization compared to healthy controls;at the end of the 3rd week of treatment,Gal-3 was statistically significantly higher than the first day of hospitalization. Our study is valuable in that it is the first study to show the change in Gal levels after treatment and to evaluate the role of Gal in BD.Gal-1 may play roles in the pathophysiology of BD.Gal-3 may be a biomarker candidate for the evaluation of the treatment response.
- 1 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (6) , 325-334
Association of OPRK1 rs963549 and rs997917 Polymorphisms With Opioid Use Disorder and Related Phenotypes
Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes. Methods: A sample of 208 individuals with (n = 100) and without (n = 108) ...
- 1 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (6) , 325-334
Association of OPRK1 rs963549 and rs997917 Polymorphisms With Opioid Use Disorder and Related Phenotypes
Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes. Methods: A sample of 208 individuals with (n = 100) and without (n = 108) ...